Literature DB >> 15048720

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate.

Rachel S Friedman1, A Gregory Spies, Michael Kalos.   

Abstract

Prostein is a prostate tissue-specific protein that is uniquely and abundantly expressed in normal and cancerous prostate tissues. Due to this expression profile, we examined the immunogenicity of prostein as a potential vaccine candidate for prostate cancer. To determine the presence of CD8 T cells specific for naturally processed prostein-derived epitopes in healthy individuals, we developed and applied an in vitro stimulation protocol. Using this protocol, we identified CD8 T cells specific for prostein in the peripheral blood of a male and a female donor. Prostein-specific CD8 T cell clones specifically recognized prostein-expressing targets, including prostate tumor cell lines expressing the relevant HLA alleles. CD8 T cell clones isolated from the male donor were significantly less effective in recognizing target cells compared to cells isolated from the female donor and appeared to recognize subdominant epitopes. The identification of a prostein-specific CD8 T cell repertoire supports the development of prostein in vaccination strategies against prostate cancer. Furthermore, the naturally processed peptide epitopes identified provide tools for the development of peptide-based vaccination strategies against prostate cancer and for monitoring of prostein-specific responses in vaccinated patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048720     DOI: 10.1002/eji.200324768

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

Authors:  Jeanne Menez-Jamet; Catherine Gallou; Aude Rougeot; Kostas Kosmatopoulos
Journal:  Ann Transl Med       Date:  2016-07

2.  Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

Authors:  Alan M Watson; Lawrence M Mylin; Megan M Thompson; Todd D Schell
Journal:  J Immunol       Date:  2012-11-21       Impact factor: 5.422

3.  PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.

Authors:  Arash Memarnejadian; Courtney E Meilleur; Christopher R Shaler; Khashayarsha Khazaie; Jack R Bennink; Todd D Schell; S M Mansour Haeryfar
Journal:  J Immunol       Date:  2017-09-22       Impact factor: 5.422

Review 4.  Adoptive T-cell therapy for Leukemia.

Authors:  Haven R Garber; Asma Mirza; Elizabeth A Mittendorf; Gheath Alatrash
Journal:  Mol Cell Ther       Date:  2014-08-12

Review 5.  CAR-T cell therapy: a potential new strategy against prostate cancer.

Authors:  Giuseppe Schepisi; Maria Concetta Cursano; Chiara Casadei; Cecilia Menna; Amelia Altavilla; Cristian Lolli; Claudio Cerchione; Giovanni Paganelli; Daniele Santini; Giuseppe Tonini; Giovanni Martinelli; Ugo De Giorgi
Journal:  J Immunother Cancer       Date:  2019-10-16       Impact factor: 13.751

6.  Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.

Authors:  Ming Yin; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-10-27       Impact factor: 2.644

7.  Tumor-associated antigens for specific immunotherapy of prostate cancer.

Authors:  Andrea Kiessling; Rebekka Wehner; Susanne Füssel; Michael Bachmann; Manfred P Wirth; Marc Schmitz
Journal:  Cancers (Basel)       Date:  2012-02-22       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.